Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes.
Phase of Trial: Phase II/III
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis
- 03 Aug 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2008-004412-12).
- 04 May 2012 Actual patient number 338 added as reported by ClinicalTrials.gov.
- 04 May 2012 Actual end date Oct 2010 added as reported by ClinicalTrials.gov.